

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 37/12, 37/44	A1	(11) International Publication Number: WO 98/33379 (43) International Publication Date: 6 August 1998 (06.08.98)
(21) International Application Number: PCT/US98/01891 (22) International Filing Date: 3 February 1998 (03.02.98) (30) Priority Data: 60/037,098 4 February 1997 (04.02.97) US (71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02110 (US). (72) Inventors: LERNER, Ethan, A.; 4 Nobscot Road, Newton, MA 02159 (US). QURESHI, Abrar, A.; 44 Marion Street, Brookline, MA 02146 (US). LERNER, Lisa, H.; 4 Nobscot Road, Newton, MA 02159 (US). (74) Agents: MYERS, Paul, Louis et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A NOVEL METHOD FOR TREATING EPIDERMAL OR DERMAL CONDITIONS (57) Abstract A method of treating a subject for an unwanted epidermal or dermal condition comprising administering to the subject a treatment which modulates the level of nitric oxide (NO) in the skin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A NOVEL METHOD FOR TREATING EPIDERMAL OR DERMAL CONDITIONS

5 This invention was made with government support from the National Institutes of Health. Accordingly, the government has certain rights in the invention.

BACKGROUND OF THE INVENTION

The invention relates to modulation of nitric oxide (NO) to treat epidermal and dermal conditions.

10 Organic nitrates and their gaseous metabolic end-product, nitric oxide (NO), have been implicated to date in a vast array of biologically diverse activities (Snyder et al. (1992) *Sci Amer* 5:68-77). The growth in interest in the biological effects of NO began in 1980 when it was noticed that relaxation of blood vessels (vasodilatation) no longer occurred when the endothelial layer was stripped from the vessels. The molecule
15 mediating this effect was termed endothelial-derived-relaxing-factor (EDRF). In 1987, EDRF was shown to be nitric oxide (NO).

Three nitric oxide synthase (NOS) isoforms have been characterized. A constitutive form is found in neuronal cells (nNOS) (Schmidt et al. (1991) *Biochem Biophys Res Comm* 181:1372-77), an inducible form (iNOS) is found in macrophages
20 (Xie et al. (1992) *Science* 256:225-28; Lyons et al. (1992) *J Bio Chem* 267:6370-74), while another constitutive form is produced by endothelial cells (eNOS) (Janssens et al. (1992) *J Biol Chem* 267:14519-22). These are also known as Types I, II and III, respectively (Pollock et al. (1991) *Proc Natl Acad Sci USA* 88:10480-84).

The role of NO in the vascular system has been shown to be extensive (Vane et
25 al. (1990) *New Eng J Med* 323:27-36). NO participates in the regulation of systemic blood pressure as evidenced by hypertension in mice in which the eNOS gene has been knocked out by homologous recombination (Huang et al. (1995) *Nature* 377:239-42). Decreased responsiveness to NO in the pulmonary vasculature contributes to pulmonary hypertension while the vasodilator effects of NO are necessary for penile erection (Saenz
30 et al. (1989) *New Eng J Med* 320:1025-30). Cutaneous vasculature has received some attention because the dermis has an extensive capillary network and these capillaries serve as a good model to study microcirculation in man. As in other blood vessels, the endothelium lining the dermal capillaries expresses eNOS. It has been observed that in the presence of NO, blood flow in the human skin microcirculation is remarkably
35 increased and in the presence of inhibitors of NOS, vasodilatation is impaired (Warren, JB (1994) *FASEB J* 8:247-51; Ralevic et al. (1992) *Br J Pharmacol* 106:650-655).

Large amounts of NO are produced when macrophages are cultured with interferon-gamma (IFN- γ), tumor necrosis factor-alpha (TNF- α) or low doses of lipopolysaccharide (LPS) (Stuehr et al. (1985) *Proc Natl Acad Sci USA* 82:7738-42). Production of NO by macrophages is toxic to bacteria and parasites (Liew et al. (1991) *Immunol Today* 12(3):A17-A21). For example, resistance of mice to *Leishmania major* infection correlates with the induction of NOS in macrophages (Liew et al. (1990) *J Immunol* 144:4794-97). In mice where the iNOS gene has been knocked out, leishmania infection is severe.

The fact that NO is a neuronal messenger was first appreciated when it was shown that cerebellar granule cells release NO after exposure to glutamate agonists (Garthwaite, J. (1991) *Trends Neurosci* 14:60-67). NOS containing neurons are found throughout the central and peripheral nervous systems (Bredt et al. (1992) *Neuron* 8:3-11). NO plays a key role in nervous system morphogenesis and synaptic plasticity.

SUMMARY OF THE INVENTION

In one aspect, the invention features, a method of treating a subject, e.g., a human, for an unwanted epidermal or dermal condition. The method includes administering to the subject, a treatment which modulates the level of nitric oxide (NO) in the skin. Conditions characterized by unwanted cells, e.g., melanocytes or keratinocytes, the proliferation of such cells, or a deficiency in apoptosis of such cells, or unwanted pigmentation, are treated by increasing the level of NO in the skin. Conditions characterized by the lack of or by an insufficient number of dermal or epidermal cells, e.g., melanocytes or keratinocytes, or a lack of pigmentation, are treated by reducing the level of NO in the skin.

In preferred embodiments the epidermal or dermal condition is: a melanocyte-related disorder; a disorder characterized by a lack of skin or hair pigmentation, e.g., graying or other loss of pigmentation of the hair; a disorder characterized by unwanted or excess skin or hair pigmentation; a disorder characterized by a deficiency in the number or activity of melanocytes; a disorder characterized by unwanted melanocyte cell death; a disorder characterized by unwanted melanocyte apoptosis.

In preferred embodiments the condition is: vitiligo; post-inflammatory hypopigmentation; post-inflammatory hyperpigmentation; or idiopathic guttate hypomelanosis (IGH).

In preferred embodiments the epidermal or dermal condition is: a keratinocyte-related disorder; a disorder characterized by deficiency in the number or activity of keratinocyte; a disorder characterized by unwanted keratinocyte cell death; a disorder characterized by unwanted keratinocyte apoptosis.

In preferred embodiments the condition is characterized by unwanted keratinocyte proliferation, caused, e.g., by a deficiency in keratinocyte apoptosis.

In preferred embodiments the condition is: an inflammatory skin disorder, e.g., eczema or psoriasis; or toxic epidermal necrolysis (TEN).

5 In preferred embodiments the condition is lichen planus.

In preferred embodiments the condition is sunburn.

In preferred embodiments the condition is graft versus host disease (GvHD).

In other preferred embodiments: the treatment can be administered topically or intravenously. Preferably, the treatment is repeated, e.g., it is repeated at least 1, 2, 3, 4,
10 or 5 times.

In preferred embodiments the treatment includes: the administration of a compound; the administration of a compound which inhibits the level of NO in the skin of the subject, e.g., an inhibitor of NO synthase or an NO scavenger, e.g., a heme compound, e.g., hemoglobin, thereby preferably decreasing the level of cell death (or
15 increasing the number of viable) skin cells, e.g., melanocytes or keratinocytes.

In other preferred embodiments the treatment includes: the administration of a compound, e.g., the administration of a compound which increases the level of NO in the skin of the subject, e.g., an NO donor compound, e.g., sodium nitroprusside (SNP) or a derivative thereof, thereby preferably increasing the level of cell death (or decreasing
20 the number of viable) skin cells, e.g., melanocytes or keratinocytes.

In preferred embodiments the level of NO in the skin is modulated by inhibiting the production of NO by a Langerhans cell or a keratinocyte.

In other preferred embodiments the modulation results in: a decrease in the level of melanocytes or keratinocytes; a decrease in the level of cell death of melanocytes or
25 keratinocytes.

In another aspect, the invention features, a method of treating a subject for a loss of pigmentation in the hair. The method includes administering to the subject a treatment which decreases the level of nitric oxide (NO) in the skin, e.g., in the scalp.

The treatment can be administered topically or subcutaneously, e.g., to the scalp,
30 or intravenously and can be repeated, e.g., repeated at least 1, 2, 3, 4, or 5 times.

In preferred embodiments the treatment includes: the administration of a compound; the administration of a compound which inhibits the level of NO in the skin of the subject, e.g., an inhibitor of NO synthase or an NO scavenger, e.g., a heme compound, e.g., hemoglobin, thereby preferably decreasing the level of melanocyte cell
35 death.

In preferred embodiments the level of NO in the skin is modulated by: inhibiting the production of NO by a Langerhans cell or a keratinocyte.

In another aspect, the invention features, a method of treating a subject, e.g., a human, for sunburn or other exposure to ultra-violet light, or for unwanted effects of aging on the skin. The method includes administering to the subject a treatment which decreases the level of nitric oxide (NO) in the skin.

- 5 The treatment can be administered topically or subcutaneously, e.g., to the affected area of the skin, or intravenously and can be repeated, e.g., repeated at least 1, 2, 3, 4, or 5 times.

10 In preferred embodiments the treatment includes: the administration of a compound; the administration of a compound which inhibits the level of NO in the skin of the subject, e.g., an inhibitor of NO synthase or an NO scavenger, e.g., a heme compound, e.g., hemoglobin, thereby preferably decreasing the level of melanocyte or keratinocyte cell death.

In preferred embodiments the level of NO in the skin is modulated by: inhibiting the production of NO by a Langerhans cell or a keratinocyte.

- 15 In another aspect, the invention features, a method of treating a subject, e.g., human, for toxic epidermal necrolysis. The method includes administering to the subject a treatment which decreases the level of nitric oxide (NO) in the skin.

20 The treatment can be administered topically or subcutaneously, e.g., to the affected area of the skin, or intravenously and can be repeated, e.g., repeated at least 1, 2, 3, 4, or 5 times.

25 In preferred embodiments the treatment includes: the administration of a compound; the administration of a compound which inhibits the level of NO in the skin of the subject, e.g., an inhibitor of NO synthase or an NO scavenger, e.g., a heme compound, e.g., hemoglobin, thereby preferably decreasing the level of melanocyte or keratinocyte cell death.

In preferred embodiments the level of NO in the skin is modulated by: inhibiting the production of NO by a Langerhans cell or a keratinocyte.

- 30 In another aspect, the invention features, a method of treating a subject for vitiligo. The method includes administering to the subject a treatment which decreases the level of nitric oxide (NO) in the skin.

The treatment can be administered topically or subcutaneously, e.g., to the affected area of the skin, or intravenously and can be repeated, e.g., repeated at least 1, 2, 3, 4, or 5 times.

35 In preferred embodiments the treatment includes: the administration of a compound; the administration of a compound which inhibits the level of NO in the skin of the subject, e.g., an inhibitor of NO synthase or an NO scavenger, e.g., a heme

compound, e.g., hemoglobin, thereby preferably decreasing the level of melanocyte or keratinocyte cell death.

In preferred embodiments the level of NO in the skin is modulated by: inhibiting the production of NO by a Langerhans cell or a keratinocyte.

- 5 In another aspect, the invention features, a method of altering the appearance of the skin, preferably decreasing pigmentation, or generally, lightening the skin, in a subject, e.g., a human. The method includes administering to the subject, a treatment which increases the level of nitric oxide (NO) in the skin.

10 In preferred embodiments: the treatment can be administered topically or intravenously. Preferably, the treatment is repeated, e.g., it is repeated at least 1, 2, 3, 4, or 5 times.

In other preferred embodiments the treatment includes: the administration of a compound, e.g., the administration of a compound which increases the level of NO in the skin of the subject, e.g., an NO donor compound, e.g., sodium nitroprusside (SNP) or
15 a derivative thereof, thereby preferably increasing the level of cell death (or decreasing the number of viable) skin cells, e.g., melanocytes or keratinocytes.

In another aspect, the invention features, a method of altering the appearance of the skin, preferably increasing pigmentation, or generally, darkening the skin, in a subject, e.g., a human. The method includes administering to the subject, a treatment
20 which decreases the level of nitric oxide (NO) in the skin.

In preferred embodiments: the treatment can be administered topically or intravenously. Preferably, the treatment is repeated, e.g., it is repeated at least 1, 2, 3, 4, or 5 times.

In preferred embodiments the treatment includes: the administration of a
25 compound; the administration of a compound which inhibits the level of NO in the skin of the subject, e.g., an inhibitor of NO synthase or an NO scavenger, e.g., a heme compound, e.g., hemoglobin, thereby preferably decreasing the level of cell death (or increasing the number of viable) skin cells, e.g., melanocytes or keratinocytes.

30 In another aspect, the invention features, a method of altering the appearance of the hair, preferably decreasing pigmentation, or generally, lightening the hair, in a subject, e.g., a human. The method includes administering to the subject, a treatment which increases the level of nitric oxide (NO) in the skin, e.g., the scalp.

In preferred embodiments: the treatment can be administered topically or intravenously. Preferably, the treatment is repeated, e.g., it is repeated at least 1, 2, 3, 4,
35 or 5 times.

In other preferred embodiments the treatment includes: the administration of a compound, e.g., the administration of a compound which increases the level of NO in

the skin of the subject, e.g., an NO donor compound, e.g., sodium nitroprusside (SNP) or a derivative thereof, thereby preferably increasing the level of cell death (or decreasing the number of viable) skin cells, e.g., melanocytes or keratinocytes.

5 In another aspect, the invention features, a method of altering the appearance of the hair, preferably increasing pigmentation, or generally, darkening the hair, in a subject, e.g., a human. The method includes administering to the subject, a treatment which decreases the level of nitric oxide (NO) in the skin, e.g., the scalp.

In preferred embodiments: the treatment can be administered topically or intravenously. Preferably, the treatment is repeated, e.g., it is repeated at least 1, 2, 3, 4,
10 or 5 times.

In preferred embodiments the treatment includes: the administration of a compound; the administration of a compound which inhibits the level of NO in the skin of the subject, e.g., an inhibitor of NO synthase or an NO scavenger, e.g., a heme compound, e.g., hemoglobin, thereby preferably decreasing the level of cell death (or
15 increasing the number of viable) skin cells, e.g., melanocytes or keratinocytes.

The inventors have discovered that transgenic animals having one or more constructs which include a skin promoter coupled to a gene which increases the level of NO in the skin, can be used to evaluate a compound for use in enhancing the health or appearance of the hair or skin, particularly pigmentation of the hair or skin.

20 Accordingly, the invention features, a method of evaluating a compound for its effect on the hair or skin. The method includes:

providing a transgenic animal having a gene which increases the level of NO in the skin coupled to a skin promoter;

administering the compound to the transgenic animal; and
25 evaluating the compound for its effect on the hair or skin.

In preferred embodiments, the compound is administered by: applying the compound to the hair or skin of the transgenic animal; systemically administering the compound; orally administering the compound; or injecting the compound, preferably dermally or subcutaneously. In preferred embodiments, the compound is administered
30 using a suitable delivery vehicle, for example, a surfactant or an agent which increases permeability in the skin, e.g., an SDS or DMSO containing formulation.

In preferred embodiments, the transgenic animal is a non-human transgenic animal. For example, the transgenic animal can be a transgenic mini-pig, a transgenic guinea-pig, a transgenic rat, or a transgenic mouse. The most preferred animals are
35 mice.

In particularly preferred embodiments, the skin promoter is: an involucrin promoter; a keratin, e.g., a keratin 14, promoter; a tyrosinase promoter.

In preferred embodiments gene encodes: a nitric oxide synthase, e.g., inducible nitric oxide synthase.

In preferred embodiments, the method further includes one or more subsequent administrations of the compound to the transgenic animal. In preferred embodiments, the compound is administered to the transgenic animal for a period of at least one, two, three, or four weeks. The compound can be administered at a constant level or at a range of different levels.

In preferred embodiments, the compound is: a cosmetic; a non-toxic substance; a substance approved for human drug or cosmetic use in one or more jurisdictions.

In another aspect, the invention features, a non-human transgenic animal described herein, e.g., a transgenic animal having gene which increases the level of NO in the skin, e.g. the iNOS gene, coupled to a skin promoter. e.g. an involucrin promoter; a keratin, e.g., a keratin 14, promoter; a tyrosinase promoter.

In preferred embodiments, the transgenic animal is a non-human transgenic animal. For example, the transgenic animal can be a transgenic mini-pig, a transgenic guinea-pig, a transgenic rat, or a transgenic mouse, e.g., a senescence accelerated mouse, or a transgenic mutant mouse which exhibits a phenotype of accelerated aging. The most preferred animals are mice.

In another aspect, the invention features a promoter- gene construct described herein.

Methods of the invention can be performed *in vivo*, with whole animals, or *in vitro*, that is, with tissue, e.g., skin, or cells, which are derived from a transgenic animal described herein or with cells, preferably skin cells or tissue, from cells transformed with a promoter/gene construct.

The methods of the invention allow rapid and efficient evaluation of compounds for their effect on skin or hair.

As used herein, the term "epidermal or dermal condition" refers to any unwanted condition, e.g., a disorder, a disease, an autoimmune disorder, or a condition of the hair or skin associated with aging, stress, or exposure to sun.

As used herein, the term "modulates" refers to increasing or decreasing levels of NO in the skin (or hair) of a subject. For example, NO levels in the skin can be decreased by administration, e.g., topical or intravenous administration, of an inhibitor of NO synthase or an NO scavenger, e.g., a heme compound, e.g., hemoglobin. The levels of NO in the skin can be increased by administration, e.g., topical or intravenous, of an NO donor, e.g., sodium nitroprusside (SNP) or a derivative thereof. Modulation can occur at the level of the gene, e.g., by gene or cell therapy, e.g., to increase NO synthesis, at the level of gene expression, e.g., by administration of antisense molecules

which inhibit NOS expression, at the enzyme level, e.g., by the addition of an inhibitor of NOS, or at the product level, e.g., by the addition of a scavenger molecule or by absorbing NO, or by administration of NO.

The term "subject," as used herein, is intended to include mammals having or
5 being susceptible to an unwanted epidermal or dermal condition. Examples of such subjects include humans, dogs, cats, pigs, cows, horses, rats and mice.

The term "treating a condition" is intended to include preventing, inhibiting, reducing, or delaying the progression of the condition.

As used herein, a "transgenic animal" is an animal, e.g., a non-human mammal,
10 e.g., a mini-pig, a guinea-pig, or a rodent, e.g., a mouse or a rat, in which one or more, and preferably essentially all, of the cells of the animal include a transgene. The transgene can be introduced into the cell, directly or indirectly by introduction into a precursor of the cell, e.g., by microinjection, transfection or infection, e.g., by infection with a recombinant virus. The term genetic manipulation is directed to the introduction
15 of a recombinant DNA molecule. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA.

As used herein, the term "rodent" refers to all members of the phylogenetic order *Rodentia*.

As used herein, the term "skin promoter" refers to a promoter which is
20 transcriptionally active in the skin. It need not be skin-specific. The gene in which the promoter is naturally found can be a gene involved in the maintenance, or proper functioning of the skin.

As used herein, "administering a compound to an animal" refers to dispensing, delivering or applying a treatment to an animal or cell. Administration can be by topical
25 administration, by parenteral or oral route, intramuscular injection, subcutaneous/intradermal injection, intravenous injection, buccal administration, transdermal delivery or administration by the intranasal or respiratory tract route. The most preferred administrations are topical application or subcutaneous or intradermal injection.

30 The inventors have discovered that NO is an important mediator in skin physiology. Methods of the invention can treat pathological processes in the skin, resolve diagnostic dilemmas and enhance therapeutic measures available to dermatologists.

There are many patients whose skin disease is exacerbated by stress. One
35 possible explanation for this phenomenon is that nerves release mediators that stimulate Langerhans cells to produce iNOS resulting in the production of large amounts of NO

with associated alteration of normal physiological processes or immune function. Thus, blockade of NOS will have beneficial effects.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are described in the literature. See, for example, *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); *DNA Cloning*, Volumes I and II (D. N. Glover ed., 1985); *Oligonucleotide Synthesis* (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No. 4,683,195; *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Transcription And Translation* (B. D. Hames & S. J. Higgins eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu et al. eds.), *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE INVENTION

The drawings will first be briefly described.

Drawings:

Figure 1A and 1B: A graph depicting LC and SX-52 cells NO production in the presence of LPS. A. Nitrite levels of supernatants from SX-52 cells after 24 hours (200,000 cells/well). B. NO production increases over time in XS-52 cells (50,000 cells/well). Experiments were performed in triplicate, and bars represent the average with standard deviation.

Figure 2: A bar graph depicting inhibition of NO production in XS-52 cells by L-NAME. Supernatants from SX-52 cells incubated overnight at 37°C in LPS (1 µg/ml) with L-NAME- an inhibitor of iNOS, were assayed for nitrite levels using the Griess reaction (200,000 cells/well). The bars represent an average of three wells on a microtiter plate. 1=LPS(-), 2=LPS(+) 1 µg/ml, 3=LPS + L-NAME (5 mM), 4=LPS + D-NAME (5 mM).

Figure 3: A bar graph depicting IL-10 suppression of NO production in XS-52 cells. IL-10 suppresses NO production as seen by bar 3, compared to optimal NO production in the presence of LPS alone (bar 2). IL-10 (10 ng/ml) actually effects iNOS induction, but the effect can also be seen at the level of the final product, NO. All bars are shown with standard deviation.

Figure 4: A photograph of a gel depicting IL-10 inhibition of iNOS expression. Western blot with a control (1) RAW 264.7 (mouse macrophage cell-line) cell extract demonstrates increase in iNOS expression in the presence of LPS (3), which is inhibited by IL-10. L-NAME and D-NAME do not affect iNOS levels in XS-52 cells. 1=RAW 264.7 cells(LPS), 2=LPS(-), 3=LPS(+), 4=LPS + IL-10 (50 ng/ml), 5=LPS + L-NAME (5 mM), 6=LPS + D-NAME (5 mM).

Langerhans Cells and NO

Langerhans cells (LC) are dendritic cells of the skin that play a key role in cutaneous immune responses. They can be considered as sentinels standing guard against external stimuli. Their function is to sample, respond themselves and to inform the rest of the immune system of changes in the environment. LC reside in the basal and suprabasal layers of the epidermis and form a network of dendrites, through which they interact with adjacent keratinocytes and nerves. They are mobile, and can migrate to the T cell dependent area of lymph nodes. Like macrophages they are bone-marrow derived, constitutively express MHC-II and have potent antigen presenting properties. Unlike macrophages however, LC have the ability to sensitize naive T cells.

In 1981, Tannenbaum found that a patient who suffered from infectious diarrhea excreted very high levels of urinary nitrates, opening the door to a series of investigations which resulted in the discovery of nitric oxide (NO) in macrophages (Snyder et al. (1992) *Sci Amer* 5:68-77). It is now known that macrophages express an inducible isoform of the enzyme nitric oxide synthase (iNOS) whose gene has been cloned and the expression of which is dramatically increased in the presence of the endotoxin, lipopolysaccharide (LPS)(Xie et al. (1992) *Science* 256:225-28; Lyons et al. (1992) *J Bio Chem* 267:6370-74). iNOS is responsible for converting L-arginine into NO via a series of redox reactions involving cofactors such as tetrahydrobiopterin. Nitric oxide is a short-lived, highly reactive gas that has the ability to diffuse across cells and can cause effects in neighboring cells. Thus it may be produced distant to its actual site of action. Potentially toxic, NO has rich redox and additive chemical properties which allow it to exert paradoxical effects in related biological systems. It is both a messenger and an effector (toxin). It is a mediator in vasodilatation, a neurotransmitter in the central and peripheral nervous systems and an active agent in macrophage cytotoxicity and neurotoxicity. NO has also been identified as a neurotransmitter and an

isoform of the enzyme iNOS is expressed in nerves (neuronal NOS, ncNOS). NO from macrophages has been implicated in the non-specific defense against parasitic disease as it participates in the production of free radicals which are directly toxic to bacteria and parasites. Thus, NO mediates both servoregulatory and cytotoxic functions and this may
5 be due to its biochemical properties which allow it to exert paradoxical effects in related systems.

Though NO has not been described with great detail in the skin, it has been demonstrated to play a role in cutaneous vasodilatory responses, Substance P induced edema formation in mouse skin and mustard-oil induced inflammation in rat skin. The
10 skin is the first defense against a hostile environment. Therefore, it must have an efficient immune system to tackle a variety of potentially harmful organisms and substances. Langerhans cells form the afferent arm of this system. In the epidermis, although macrophages can be recruited, the Langerhans cell is the major antigen presenting cell. Nitric oxide is an important effector molecule in macrophages.

15 Although not wishing to be bound by theory, the Applicants believe that keratinocytes may also be responsible for the production of NO by nitric oxide synthase.
Inhibitors of NO Synthesis

As used herein, the term "NO synthase inhibitor" refers to any competitive or non-competitive inhibitor of NO synthase. The effectiveness of a compound, and its
20 relative potency as an NOS inhibitor, can be tested and routinely determined by measuring inhibition of NOS activity by monitoring the conversion of arginine to citrulline by NOS in, for example, cerebellar homogenates. A reduction in citrulline formation indicates inhibitory activity of the compound. The percent reduction in citrulline formation, compared to the amount of citrulline formed in the absence of the
25 compound being tested, indicated the potency of the compound as an NOS inhibitor.

Inhibitors of nitric oxide synthase which can be used in this invention include substrate analogs, such as aminoguanidine, N^G-nitro-L-arginine, N^G-methyl-L-arginine, N^G-nitro-L-arginine, N^G-nitro-L-arginine methyl ester, and N^G-iminoethyl-L-ornithine, flavoprotein binders, such as diphenylene iodonium, iodonium diphenyl and di-2-thienyl
30 iodonium, calmodulin binders, such as calcineurin, trifluoroperazine, N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide and N-(6-aminoethyl)-1-naphthalenesulfonamide, heme binders, such as carbon monoxide, depleters and analogs of tetrahydrobiopterin, such as 2,4-diamino-6-hydroxypyrimidine, and induction inhibitors, such as corticosteroids, TGF- β -1, -2, 3, interleukin-4, interleukin-10 and macrophage
35 deactivation factor (Nathan, the FASEB Journal, Vol. 6, Sept. 1992, pp. 3051-3064). Preferred are the substrate analogs of nitric oxide synthase, N^G-amino-L-arginine, N^G-methyl-L-arginine, N^G-nitro-L-arginine N^G-nitro-L-arginine methyl ester, and N^G-

iminoethyl-L-ornithine. Particularly preferred are N^G-amino-L-arginine, N^G-methyl-L-arginine, N^G-nitro-L-arginine, and aminoguanidine. Most preferred is N^G-methyl-L-arginine. Many of these inhibitors are available from commercial sources, e.g., Calbiochem, Sigma, and Aldrich.

- 5 Pharmaceutically acceptable salts may also be administered. Examples of suitable salts include acid salts, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfate and acetate salts, as well as basic salts, such as amine, ammonium, alkali metal and alkaline earth metal salts.

- 10 In another embodiment, an inhibitor of the NO synthase cofactor tetrahydropterin can be used. One such inhibitor is aminopterin.

Nitric Oxide (NO) Scavengers

- 15 As used herein, the term "NO scavenger" refers to a molecular entity that binds with free NO so as to reduce the concentration of NO locally or systemically. Such scavengers include, but are not limited to, metalloproteins, in particular heme containing proteins such as but not limited to hemoglobin, myoglobin, cytochrome-P-450, heme albumin, heme-containing peptides such as undecapeptide of cytochrome C, as well as water soluble hemoglobin analogs such as strapped heme (e.g., Traylor and Traylor (1982) *Ann. Rev. Biophys. Bioeng.* 11:105-127) and picket fence porphyrin (Collman et al. (1975) *J. Am. Chem. Soc.* 97:1427-1439). In a preferred embodiment, the scavenger selected for use is one which, *in vivo*, *in vitro*, or animal model experiments, is shown to be capable of causing vascular stasis that is not reversed by L-arginine.

- 20 Use of many scavengers according to the present invention has the advantage of restriction NO reduction to the vasculature, without affecting intracellular NO production or extravascular NO activity. Thus, NO activity as a transduction mechanism for soluble guanylate cyclase in the nervous system and the function of immune cells, such as macrophages, will be minimally affected, thus reducing possible side effects of therapy with an NO scavenger.

Other Inhibitors of NO Activity

- 25 In addition to inhibitors of NO synthase, methods of the invention can use inhibitors of the second messenger system activated by NO, particularly the second messengers (downstream signal mediators) guanylate cyclase and cyclic CMP. A non-limiting example of guanylate cyclase inhibition is methylene blue. Cyclic GMP activity can be inhibited by aminoguanidine, such as M&B 22948.

Reversal of NO Synthesis Inhibition in Normal Tissue

- 35 Methods of the invention can include the therapeutic administration of an NO synthase inhibitor (a competitive inhibitor, e.g., a substrate analog) followed by

administration of an NO synthase substrate so as to selectively reverse any effect of the inhibitor on normal tissue.

NO synthase substrates which can be used, but are not limited to, are guanidine succinate and L-arginine.

5 NO Donors

Methods of the invention can include the therapeutic administration of an NO donor. As used herein, the term "NO donor" refers to a molecular entity which is capable of releasing NO. Examples of NO donors include sodium nitroprusside (SNP) or derivatives thereof.

10 Transgenic animals

Transgenic animals which can be used in the methods of the invention include non-human mammals, such as pigs, e.g., mini-pigs, or guinea-pigs; or rodents, e.g., mice or rats. The transgenic animals can be homozygous or heterozygous for the transgene. Mice are a preferred subject animal.

- 15 Methods for the preparation of a variety of animals are known in the art. A protocol for the production of a transgenic pig can be found in White and Yannoutsos, *Current Topics in Complement Research: 64th Forum in Immunology*, pp. 88-94; US Patent No. 5,523,226; US Patent No. 5,573,933; PCT Application WO93/25071; and PCT Application WO95/04744. A protocol for the production of a transgenic rat can be
20 found in Bader and Ganten, *Clinical and Experimental Pharmacology and Physiology*, Supp. 3:S81-S87, 1996. A protocol for the production of a transgenic cow can be found in *Transgenic Animal Technology, A Handbook*, 1994, ed., Carl A. Pinkert, Academic Press, Inc. A protocol for the production of a transgenic sheep can be found in *Transgenic Animal Technology, A Handbook*, 1994, ed., Carl A. Pinkert, Academic
25 Press, Inc. All patents and references are incorporated herein by reference.

Pharmaceutical Compositions

- The compounds of the claimed invention can be administered alone or in a suitable pharmaceutical composition. Modes of administration are those known in the art, such as enteral, parenteral, e.g., intravenous, or topical application. Intravenous
30 administration is preferred and topical administration is particularly preferred.

- Preferably the compound is prepared in an admixture with a pharmaceutically acceptable carrier. The term "carrier" refers to diluents, excipients and the like for use in preparing admixtures of a pharmaceutical composition. Suitable pharmaceutical carriers can be employed and include, but are not limited to water, salt solutions, alcohols,
35 polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, etc. The pharmaceutical preparations

can be sterilized and if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, flavorants, coloring, and/or aromatic substances and the like which do not deleteriously react with the active compounds.

5 For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. Ampoules are convenient unit dosages. Oral applications are preferably administered in the forms of capsules, tablets and/or liquid formulations. Unit form dosages are preferred.

10 The dosage and length of treatment depends on the disease state being treated. The duration of treatment may be a day, a week or longer and may, as in the case of a chronic progressive condition last over the entire lifetime of the patient. The compounds of the invention may also be administered on a daily basis as long as the symptoms persist. The inhibitors are administered in a therapeutically effective amount, a typical
15 human dosage of NO synthase inhibitor ranging from about 0.01 mg/kg of body weight to about 10 mg/kg, in single or divided doses. The dosage will vary depending on the NO synthase inhibitor or scavenger to be used and its relative potency. Dosage and length of treatment are readily determinable by the skilled practitioner based on the condition and stage of disease.

20 Generally, the compound is administered in a single bolus dose, although the present invention also contemplates sustained administration, e.g., via an IV drip or pump, or administration in multiple boluses.

The compounds of the invention are preferably incorporated in a topical composition or a cosmetic composition which includes a non-toxic dermatologically
25 acceptable vehicle or carrier which is adapted to be spread upon the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. One such vehicle is disclosed in PCT/US93/05068. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.

30 The concentration of the compound of the invention in the topical composition may be varied over a wide range up to a saturated solution, preferably from 0.01% to 30% by weight or even more. The maximum amount effectively applied is limited only by the rate at which the compound of the invention penetrates the skin. Generally, the effective amounts range from 10 to 3000 micrograms or more per square centimeter of
35 skin.

Techniques and formulations for administering the compositions may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA, latest edition.

Assaying Nitric Oxide (NO) Levels

5 The short half life (six seconds), instability in the presence of oxygen and small amounts produced make direct measurement of NO difficult but possible with NO-sensitive electrodes (Archer S. (1993) *FASEB J* 7:349-60). Functional assays focus on the presence of nitric oxide synthase (NOS), the enzyme which catalyzes the formation of NO via oxidation of the guanidino-nitrogen in L-arginine producing NO and
10 citrulline. Indirect assays employ the Griess Reaction to measure nitrite, one of the oxidation products of NO (Green et al. (1982) *Analytical Biochem* 126:131-38). Determination of levels of the second messenger cyclic GMP (cGMP) assess the effect of NO on the enzyme guanylate cyclase that is activated by NO to produce cGMP (McKee et al. (1994) *Proc Natl Acad Sci USA* 91:12056-60). Detection of NOS RNA
15 on Northern blots and NOS protein on Western blots provides additional avenues to study NO regulation. Histochemistry can be employed to examine the expression of NOS *in situ*. All of these tools can be employed to study the contribution of NO to cutaneous physiology.

 This invention is further illustrated by the following examples which in no way
20 should be construed as being further limiting. The contents of all cited references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

EXAMPLES

25

THE FOLLOWING MATERIALS AND METHODS WERE USED IN EXAMPLES 1-6:

Animals.

 Eight to twelve week old BALB/c mice were obtained from The Jackson
30 Laboratory (Bar Harbor, ME) for preparation of LC.

Tissue culture reagents, media and chemicals.

 Tissue culture reagents were obtained from Life Technologies, Grand Island, NY; complete media (CM), consisted of RPMI 1640 supplemented with 10% fetal calf
35 serum (FCS), hepes (10 mM), streptomycin (100 µg/ml), penicillin (100 U/ml), 2-mercapto-ethanol (0.1 M), sodium pyruvate (1 mM), non-essential amino acids (0.1

mM) and L-glutamine (2 mM). Recombinant murine IL-10 was obtained from Biosource and LNAME and D-NAME from Sigma, St. Louis, MO.

Antibodies and related reagents were as follows: anti-Thy-1.2 mAb, (Sigma), low-toxicity rabbit complement (Cedarlane, Hornby, Ontario, Canada), mouse anti-mouse I-A^d (Pharmingen, San Diego, CA), goat anti-mouse IgG conjugated to magnetic microspheres (Dynabeads M-450; Dynal A.S, Oslo, Norway), Lympholyte M (density 1.0875, Cedarlane, Hornby, ON) and anti-iNOS FITC conjugated monoclonal antibody (IgG) to a 21kDa protein fragment corresponding to amino acids 961-1144 of mouse macrophage NOS (Transduction laboratories, Lexington, KY). All other chemicals were obtained from Sigma.

EC preparation.

Monocellular suspensions of murine EC were prepared as reported previously. Thy-1⁺ cells were depleted by incubation with anti-Thy-1.2 mAb and complement. Dead cells were removed over Lympholyte M. Interface cells were washed and subjected to magnetic microsphere separation to isolate LC using mouse anti-mouse I-A^d for 30 minutes followed by incubation with goat anti-mouse IgG conjugated to magnetic microspheres and subjected to a magnetic field. Cells with magnetic spheres on their surface were separated based on the magnetic field. Those with attached magnetic beads were designated LC. LC were cultured in serum-free CM.

Langerhans cell-like cell line (XS-52).

A dendritic cell line was established from newborn BALB/c epidermis as previously described. This cell line has features of Langerhans cells, i.e., cells are dendritic, contain Birbeck granules, present antigen and have many phenotypic characteristics of freshly harvested LC. The cell line was propagated in RPMI 1640 containing 10% FCS, 50 U/ml recombinant murine GM-CSF and 10% NS cell supernatant (supernatants from stromal cells cultured from newborn BALB/c mice). These cells were grown in CM without GM-CSF and NS cell supernatant for two days prior to experiments.

Reverse transcriptase-PCR.

PolyA⁺ RNA was extracted from purified LC incubated with and without LPS using magnetic microspheres (Dynabeads mRNA DIRECT kit, Dynal, Oslo, Norway) and RT-PCR was performed (Geneamp RNA PCR kit, Perkin Elmer, Branchburg, NJ). Degenerate primers (sequences received with thanks from Dr. Johanna Wolframm, Dept. of Cardiology, University of Vienna, Austria) designed to amplify iNOS, ecNOS or

ncNOS, and across mouse, rat and human species; 5' primer (Deg-A), CAYRTCAAGTAYGCCACCAACAAAGGGAA and 3' primer (Deg-C), RCCRATCTCHGTGCYCATGTACCWRC. These primers span 419 base pairs in the mouse macrophage-iNOS sequence. PCR conditions were as follows: RT reaction -
5 room temperature for 20 mins, 42°C for 15 mins, 99°C for 5 mins, and 5°C for 5 min; PCR reaction - 94°C for 3 mins, denaturing - 94°C 30 sec, annealing - 55°C 30 sec, extension - 72°C 1 min - 40 cycles, 72°C for 7 mins, 4°C. PCR products were separated in 1.5% agarose gels and stained with ethidium bromide. The fragment obtained was gel
10 purified, cloned (TA cloning kit, Invitrogen, Sorrento Valley, CA), and sequenced (Sequenase 2.0, USB, Ocala, FL).

PolyA⁺ RNA from XS-52 cells (extracted as above) was subjected to PCR with iNOS-specific primers; 5' primer (iNOS-A), AGCATCAGAGGGGATGCTGC and 3' primer (iNOS-C), ATCCTTCGGCCCACTTCCTC. These primers span 370 bp in the mouse macrophage-iNOS sequence; iNOS-A (992-1011 nucleotides), and iNOS-C
15 (1362-1343 nucleotides). These reactions were carried out in parallel with GAPDH primers to standardize intensity of bands obtained with and without LPS. After RT reaction, the reaction mixture was split for PCR for iNOS (40 cycles) and GAPDH (25 cycles). Primers for GAPDH were chosen from homologous region between human, chick and rat species; 5' primer (GAPDH-A), ACTACATGGTTTACATGTTC and 3'
20 primer (GAPDH-C), TTCCCGTTCAGCACTGGGATGA for nucleotides 183-201 and 740-719 respectively for human GAPDH cDNA. As a control, mouse ncNOS-specific primers were also used.

Immunofluorescence staining.

25 XS-52 cells were grown for two days in eight-well chamber slides (Nunc Inc., Naperville, IL), washed with cold PBS, fixed with 1:1, methanol:acetone for 5 minutes, permeabilized with 0.2% Triton-X 100 in PBS for 20 minutes and blocked with 2% horse serum. After two washes in 0.2% BSA in PBS, anti-iNOS FITC was added to the wells at a 1:100 dilution and incubated at 37°C for 1 hour. After three washes with PBS,
30 each 10 minutes, the slides were mounted with Gel/mount (Biomedex, Foster City, CA).

Griess reaction (nitrite measurement).

XS-52 cells were incubated in 24 well plates, in both, the presence and absence of LPS (1 µg/ml). After 24 hrs at 37°C, the supernatants from respective wells were
35 assayed for the presence of nitrite using the Saville modification of the Griess reaction (Green et. al. (1982) *Analytical Biochem* 126:131-38). 50 µl aliquots of cell-free supernatants from cells cultured with and without LPS, L-NAME or IL-10 were

incubated with 50 µl of 1% sulfanilamide in 0.5N HCl, and 50 µl of 0.02% naphthylethyene diamine dihydrochloride for 5 minutes at room temperature in flat-bottom 96 well plates. Absorbance was measured at 540 nm in an ELISA plate-reader. Sodium nitrite was used as a standard for quantification of nitrite in culture supernatants.

5

Western blot with anti-iNOS antibody.

XS-52 cells grown for two days in CM without GM-CSF in 24 well plates were treated with LPS (1µg/ml), LPS + IL-10 (50 ng/ml), LPS + L-NAME (5 mM) and LPS + D-NAME (5 mM) for 24 hrs at 37°C. Cells were washed with serum-free media, and boiling SDS gel-loading buffer (2x: 100mM Tris.Cl [pH 6.8], 200 mM Dithiothreitol, 4% SDS, 0.2% bromophenol blue, and 20% glycerol) was added. The cells were scraped into the buffer, transferred to eppendorf tubes and spun to remove debris. Supernatants were boiled for 5 mins, 20 µl aliquots were loaded on a 7% polyacrylamide gel. Proteins were transferred from the gel to a PVDF membrane (Immobilon, 0.4 µM pore size, Millipore, Bedford, MA) with an electro-blotter (Transblot SD, Bio-RAD, Hercules, CA). The membrane was blocked in 1 % bovine serum albumin (BSA) in Wash Buffer (WB: 10 mM Tris [pH 7.5], 100 mM NaCl and 0.1% Tween 20) overnight at 4 °C incubated with mouse anti-iNOS (1 :500) IgG2a monoclonal, (Transduction laboratories), diluted in 1 % BSA in WB, for 1 hr at room temperature, and washed with WB over 30 minutes. The secondary antibody, anti-mouse IgG (1 :3000) horseradish peroxidase conjugate (Bio-RAD), diluted in 5% dry milk in WB was incubated with agitation for 1 hr at room temperature. The membrane was thoroughly washed over 1 hr with WB at room temp and developed with ECL western blotting detection reagents (Amersham, Arlington Heights, IL) and exposed to film (X-OMAT AR, Eastman Kodak, Rochester, NY).

25

EXAMPLE 1: Reverse transcriptase PCR.

To examine expression of NOS in LC, RNA was extracted from freshly purified murine LC and subjected to RT-PCR with degenerate primers across iNOS, ecNOS and ncNOS. A band of approximately 400 bp was amplified which was more apparent in LPS treated as compared to non-treated cells. To identify the type of NOS, the nucleotide sequence of the PCR product was determined, and found to be identical to mouse macrophage-iNOS.

30

Primers specific for mouse-iNOS were then used to exclude the possibility that the message obtained above was obtained from contaminating keratinocytes, or other cells. In these experiments, RNA from the LC line XS-52 was subjected to PCR and a specific product was amplified. Based on the following, this band is that of iNOS:

35

First, the length of the band is about 370 nucleotides, second, the band is absent from cells not exposed to LPS and third, no products were seen in the ncNOS-specific primer lanes. Compared to the GAPDH standardized band intensities, it appears that transcription of the RNA in question is LPS dependent. As mentioned above, a faint
5 band is seen in "purified" LC not exposed to LPS lane whereas it is not seen in the XS-52 cells.

Example 2: *Anti-iNOS immunofluorescence.*

Immunofluorescence with FITC-conjugated anti-iNOS monoclonal antibody of
10 LPS stimulated XS-52 cells showed marked staining compared to that of cells incubated in LPS-free medium. The staining is cytoplasmic sparing the nucleus, and appears granular in some cells. This result suggests that LC express iNOS which is inducible by LPS. Staining of purified LC from BALC/c epidermal cell suspensions was not feasible as the magnetic microspheres used for LC isolation preferentially pick up fluorescein,
15 even at maximal dilutions of the antibody.

Example 3: *XS-52 cells produce NO in vitro.*

Supernatants from XS-52 cultures were assayed for the presence of nitrite using the Griess reaction. Those from cells incubated in the presence of LPS showed a
20 dramatic increase in nitrite concentration, reflecting the increase in NO production. In contrast, cells which were not stimulated with LPS produced little NO (Figure 1A).

To estimate the time required for iNOS induction and subsequent NO production, XS-52 cells were cultured and assayed after various timepoints. Supernatants were assayed from individual wells at each time point to prevent alteration
25 in nitrite concentration due to sampling. A small increase in nitrite levels is seen after 8 hrs but significant levels are obtained after 16 hrs (Figure 1B).

Purified LC preparations were also assayed for nitrite levels after incubation in LPS. Though elevated nitrite levels are seen in these cells, the results are difficult to reproduce. Nitrite levels are not as high as those with XS-52 cells, probably as these
30 cells go through a difficult purification process, have magnetic spheres adhering to their surface and are fewer in number. Their response to LPS may thus not be optimal.

Example 4: *Suppression of NO production by L-NAME.*

To confirm *in vitro* NO production as seen in the previous experiment, nitrite
35 levels were measured in the presence of LPS and the levorotatory/dextrorotatory, methylated derivatives of L-arginine competitive inhibitors of iNOS. Two such compounds, N_w-nitro-L-arginine methyl ester (L-NAME) and N_w-nitro-D-arginine

methyl ester (D-NAME) were used. Nitrite levels in the presence of LPS were used as control levels of NO production by XS-52 cells. L-NAME inhibited NO production significantly in the presence of LPS, whereas D-NAME did not (Figure 2). This confirms that LPS-induced NO production in XS-52 cells can be inhibited specifically
5 by the L-methylated forms of L-arginine.

Example 5: *Suppression of NO production by IL-10.*

The cytokine IL-10, implicated in a variety of immunomodulatory phenomena, has been shown to affect LC antigen presentation. IL-10 has also been observed to
10 inhibit NOS induction by LPS in macrophages. The previous experiments address inhibition of NOS action only, whereas IL-10 inhibits induction of iNOS. XS-52 cells co-cultured with IL-10 and LPS reproducibly demonstrated inhibition of nitrite production (15-20%) in supernatants (Figure 3).

15 Example 6: *Effects of LPS, IL-10, and L-NAME on iNOS expression.*

A western blot was done to characterize iNOS levels in cells treated with IL-10 and L-NAME in the presence of LPS. Both L-NAME and IL-10 inhibit NO production (as above), though their mechanism of action is different. Lower levels of iNOS were seen in cells treated with IL-10, (Figure 4), whereas L-NAME did not affect iNOS
20 expression. Thus, IL-10 inhibits iNOS expression in XS-2 cells whereas L-AME competes with Larginine for the enzyme active site.

It has been shown that LC purified from murine epidermis and XS-2 cells express iNOS and produce NO in response to LPS. RNA isolated from purified LC was initially tested with degenerate primers because it was neither possible to judge whether
25 LC would express NOS at all nor what the isoform would be, iNOS, ecNOS or ncNOS. A dilemma with purifying LC from an epidermal cell suspension is the likelihood of contamination from other sources, leading to erroneous results with PCR. Therefore, once a product was seen at the expected size on electrophoresis, and sequencing data was available, identifying iNOS, a more specific PCR reaction was used, confirming the
30 presence of iNOS mRNA, as seen with macrophages (Denis M. (1994) *J Leuk Biol* 55:682-84). RNA was then isolated from the XS-52 cell line to avoid the potential for contamination and iNOS-specific primers revealed amplification of a specific product, confirming the expression of iNOS in these cells. Such expression was LPS dependent, as in macrophages. In the absence of LPS, amplification of iNOS from LC purified
35 from murine epidermis revealed a faint band not detected in XS-2 cells. This result indicates that in cultured cells, LPS is needed to stimulate iNOS transcription. However, in LC isolated from a 'recently living' mouse exposed to the environment, some LC may

have been activated *in vivo* or during isolation, causing iNOS transcription which may be the cause for the faint band seen. This result indicates a functional role of NO in LC.

These findings were further confirmed by the almost negligible intensity of immunofluorescence seen with XS-2 cells cultured in the absence of LPS. In contrast, LPS stimulation of this cell line resulted in staining with anti-NOS, revealing an increase in quantity of the translated protein. The staining was cytoplasmic, sometimes granular and occasionally dendritic processes stained strongly. The minimal staining seen in the absence of LPS indicates that a small amount of iNOS may be present constitutively, while LPS dramatically increases staining. The exact location of iNOS in the cytoplasm is not known; it may be found in granules or vesicles, either specific to NOS (e.g. nitrovesicles) or non-specific, or it may be found as a free protein. It will be interesting to examine whether iNOS is relocated between granules and cytoplasm after LPS stimulation in these cells.

The results depicted in Figure 1 demonstrate the induction of iNOS over time. These data reveal that functional iNOS is made, and is capable of producing NO *in vitro*. Allowing 6 hrs for transcription and subsequently translation, LC can respond to stimuli by producing NO within 16 hrs. Isolated LC also can be induced to produce NO after an overnight incubation with LPS. These findings present a number of exciting scenarios as iNOS can produce massive quantities of NO when induced, unlike ncNOS and ecNOS, which are constitutively expressed at a defined level. Toxic and tumorigenic effects of NO are seen at such higher levels of induction (Klostergaard J. (1993) *Res Immunol* 144(4):274-76; Cui et al. (1994) *Cancer Res* 56:2462-67; Ohshima et al. (1994) *Mutation Res* 305:253-64). As LC express iNOS and may be the only cell type in the epidermis doing so, NO produced in LC may be the most abundant form of NOS in the skin, at least in certain conditions i.e. presence of endotoxin.

The fact that NO production in LC can be blocked by using analogues of L-arginine (Moncada et al. (1993) *New Eng J Med* 329:2002-12) (Figure 2) has important implications for cutaneous pathophysiology. Topical L-AME (1%) has been shown to relieve symptoms and signs of atopic dermatitis (Morita et al. (1994) *Internat J Dermatol* 34:294). Its mechanism of action in that regard is believed to be due to inhibition of LC NO production.

The immunomodulator IL-10 consistently suppresses NO production in XS-52 cells although to a small extent, as in macrophages. IL-10 inhibits antigen presentation through inhibition of B7 (Chang et al. (1995) *Eur J Immunol* 25:394-398), a costimulatory molecule, expressed with MHC-I. A decrease in NO production secondary to IL-10 may mean that NO partly mediates the effects of IL-10. Also, IL-10

treated cells showed lower levels of iNOS as opposed to cells treated with L-NAME, though both substances inhibit NO production.

EXAMPLE 7: Nitric Oxide is Toxic for Melanocytes

5 Melanocyte susceptibility to NO was examined using NO donor compounds and NO released by a Langerhans cell-like cell line.

Sodium nitroprusside (SNP) is a donor of NO in aqueous solution. Melanocyte lysis was seen in the presence of 0.01-1mM SNP over 24 hrs, quantified by chromium release. Chromium release was seen to be both time-and SNP dose-dependent, with
10 more chromium being released from melanocytes at a higher SNP-concentration and longer time course. Maximum chromium release of up to 80-90% was seen at 16 hrs after addition of 1 mM SNP.

Langerhans cells (LC) express inducible NOS and produce large amounts of NO. Because LC lie in close proximity to melanocytes in the epidermis, it was hypothesized
15 that the large amounts of NO produced by LC may affect melanocyte function and survival, resulting in pathological manifestations. Co-culture of an LC-like cell line (XS cells) with melanocytes followed by the induction of iNOS by LPS resulted in melanocyte cell death. As melanocytes do not express iNOS, LPS had no effect on melanocytes stimulated with LPS in the absence of XS cells. Melanocyte lysis was also
20 seen when cocultures were performed across Transwells®, with no direct cell-cell contact between XS cells and melanocytes. Thus LC-induced melanocyte death was dependent on a diffusible factor consistent with NO. To confirm that this substance was indeed NO, cocultures were performed in L-arginine deficient media (reversible by addition of L-arginine) or in the presence of NO quencher, reduced hemoglobin.
25 Melanocyte toxicity was remarkably reduced under both conditions. These results indicate an NO-dependent interaction between LC and melanocytes. Thus, nitric oxide from LC and NO donors is cytotoxic for melanocytes.

Equivalents

30 Those skilled in the art will be able to recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.

35 What is claimed is:

1. A method of treating a subject for an unwanted epidermal or dermal condition comprising administering to the subject, a treatment which modulates the level of nitric oxide (NO) in the skin.
- 5 2. The method of claim 1, wherein said condition is characterized by unwanted cells, or unwanted pigmentation, and the method includes increasing the level of NO in the skin.
- 10 3. The method of claim 1, wherein said condition is characterized by the lack of or by an insufficient number of dermal or epidermal cells, or a lack of pigmentation, and the method includes reducing the level of NO in the skin.
- 15 4. The method of claim 1, wherein said condition is: vitiligo; post-inflammatory hypopigmentation; post-inflammatory hyperpigmentation; or idiopathic guttate hypomelanosis (IGH).
- 20 5. The method of claim 1, wherein said condition is: a keratinocyte-related disorder; a disorder characterized by deficiency in the number or activity of keratinocyte; a disorder characterized by unwanted keratinocyte cell death; a disorder characterized by unwanted keratinocyte apoptosis.
- 25 6. The method of claim 1, wherein said condition is characterized by unwanted keratinocyte proliferation.
- 30 7. The method of claim 1, wherein said condition is: an inflammatory skin disorder.
- 35 8. The method of claim 1, wherein said condition is eczema or psoriasis.
9. The method of claim 1, wherein said condition is toxic epidermal necrolysis (TEN).
10. The method of claim 1, wherein said condition is lichen planus.
11. The method of claim 1, wherein said condition is sunburn.

12. The method of claim 1, wherein said condition is graft versus host disease (GvHD).

13. The method of claim 1, wherein the treatment includes the administration of
5 a compound which inhibits the level of NO in the skin of the subject.

14. The method of claim 1, wherein the treatment includes the administration of an inhibitor of NO synthase or an NO scavenger.

10 15. The method of claim 1, wherein the treatment includes the administration of a compound which increases the level of NO in the skin of the subject.

16. The method of claim 1, wherein the treatment includes the administration of an NO donor compound.
15

17. A method of treating a subject for a loss of pigmentation in the hair, comprising administering to the subject a treatment which decreases the level of nitric oxide (NO) in the skin.

20 18. The method of claim 17, wherein the treatment is administered topically to the scalp.

19. The method of claim 17, wherein the treatment includes the administration of a compound which inhibits the level of NO in the skin.
25

20. A method of treating a subject for exposure to ultra-violet light, or for unwanted effects of aging on the skin, comprising administering to the subject a treatment which decreases the level of nitric oxide (NO) in the skin.

30 21. A method of decreasing skin pigmentation, comprising administering to the subject, a treatment which increases the level of nitric oxide (NO) in the skin.

22. A method of increasing skin pigmentation, comprising administering to the subject, a treatment which decreases the level of nitric oxide (NO) in the skin.
35

23. A method of decreasing hair pigmentation, comprising administering to the subject, a treatment which increases the level of nitric oxide (NO) in the skin.

24. A method of increasing hair pigmentation, comprising administering to the subject, a treatment which decreases the level of nitric oxide (NO) in the skin.

- 5 25. A method of evaluating a compound for its effect on the hair or skin,
comprising:
- providing a transgenic animal having a gene which increases the level of
NO in the skin coupled to a skin promoter;
- administering the compound to the transgenic animal; and
- 10 evaluating the compound for its effect on the hair or skin.

26. A non-human transgenic animal having gene which increases the level of
NO in the skin, coupled to a skin promoter.

1/5





FIGURE 1A

**FIGURE 1B**

3/5




FIGURE 2

4/5




FIGURE 3

5/5




FIGURE 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/01891

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 37/12, 37/44

US CL : 514/561

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/561

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,554,638 A (DEWHIRST et al.) 10 September 1996, see abstract, column 5, lines 55-67, column 6, lines 26, column 9, lines 19-56, column 13, line 40 and 59 and column 14, lines 52-67.	1-3, 13-21
X	WO 95/03810 A1 (ZHENG et al.) , (Panorama Research, Inc.) 09 February 1995, see page 1, lines 5-16, 23-28 and page 2, lines 3-31.	1-26
X	Database EMBASE on STN, No. 96245989, (Massachusetts General Hospital, Charlestown, MA), Qureshi et al., "From Bedside to the Bench and Back: Nitric Oxide and the cutis", abstract to Archives of Dermatology 132/8, pp. 889-900, 1996.	1-26

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 APRIL 1998

Date of mailing of the international search report

18 JUN 1998

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer


 DWAYNE C. JONES

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/01891

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	Database CAPLUS on STN, No. 1998:37621, (Department of Dermatoogy, Biomedical Research Center, Heinrich-Heine-University of Duesseldorf, Duesseldorf, Germany), Bruch-Gerharz et al., "Nitric oxide in human skin: current status and future prospects", abstract to J. Invest. Dermatol., 110(1), 1-7, 1998.	1-26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/01891

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

CAPLUS, BIOSIS, MEDLINE, EMBASE, WPIDS, USPATFULL search terms: (no or nitric oxide)(I)(modulat? and (skin or derm? or epiderm?) and (vitiligo or hypopigment? or hyperpigment? or idipathic guttate hypomelanos? or igh)